Detailed

Tianeptine is currently known to treat mild to moderate depressive disorders [8]. In doing so, tianeptine has been shown to:

• Modulate glutaminergic transmission
• Affect neuroplasticity
• In hippocampus and prefrontal cortex: reverses stress-induced inhibition of potentiation at excitory synapses [9].

Tianeptine’s availability is currently restricted to European countries, as well as countries in Asia and Latin America [8]. In addition, it is currently marketed under the trade name of Stablon ® in Europe, by the pharmaceutical company Servier [6]. In comparison to traditional tricyclic antidepressants (TCA) and selective serotonin reuptake inhibitors tianeptine’s mechanism of action is believed to involve the enhancement of the synaptic uptake of serotonin [10]. In the nucleus accumbens, extracellular levels of dopamine are enhanced by tianeptine, and, also modulates dopamine-3 (D3) and dopamine-2 (D2) receptors [11]. Gassaway et al (2014) were able to propose that acute and chronic tianeptine antidepressant and anxiolytic effects is mediated through the activation of -opioid receptor (MOR) [9].

Dosage

Tianeptine was explored for its efficacy in treating posttraumatic stress disorder (PTSD), and compared with the SSRI classed drug, fluoxetine [12]. Over 5.5 months, one 43 war veterans were divided into two groups; one group received a tianeptine dosage 37.5mg, whilst another group received 40mg fluoxetine [12]. Results concluded that tianeptine had a stronger effect on anxiety, and is on par in effectiveness in treating PTSD as fluoxetine [12]. A similar study assessing tianeptine in major depression over six weeks, used an effective 37.5mg/day tianeptine dose in 178 patients [13]. Tianeptine was compared to fluoxetine, and both antidepressants showed similar effectiveness and were well-tolerated [13]. Another study sought to evaluate the antidepressant effects and safety profile of tianeptine and paroxetine [14]. This study involved a 3-month trial, in which 277 patients were randomly assigned with 12.5mg tianeptine (3x daily) or paroxetine 20mg (once daily, with two placebo capsules). Results indicated that tianeptine was as effective and safe as paroxetine for the treatment of major depression [14]. Tianeptine was also evaluated for its effects on car driving performance [15], in a double-blind four-way crossover study [15]. 16 healthy volunteers randomly received acute dose of 12.5mg and high dose of 37.5mg tianeptine capsules, and results showed that tianeptine doses of up to 37.5mg did not have negative effect on driving skills [15]. Over a three-month trial, tianeptine was hypothesised to improve short-term memory, reaction time and attention in patients with depression [16]. Authors chose a 37.5mg tianeptine dose over the study period in 20 patients, and results indicated that tianeptine improved cognitive functioning in depressed patients [16]. Lastly, literature expounds that clinical trials involving the administration of tianeptine have used between 25-50mg/day, which is said to be much lower than abuse cases [1].

Safety

Tianeptine has recently been recognised for its abuse potential [1]. In addition, as tianeptine has been reviewed for its potential therapeutic effect with depression, it has also been argued that tianeptine only encourages neuroplasticity [1]. Case reports on tianeptine have reported significantly higher doses – 3000mg, 1875mg, 2612.5mg, 750mg, and 3000mg per day, with abuse cases also reporting the concurrent ingestion of other substances [1].

Side effects

Tianeptine has been documented as being generally well tolerated by patients, with minimal side effects when compared to TCAs and SSRIs [10]. Notable adverse effects of tianeptine (25mg 3-times/day) include: headaches, abdominal discomfort, drowsiness, nausea, dry mouth, insomnia, and vomiting [14]. Tianeptine withdrawal effects have been reported as an example case of a 32-year old male who was previously diagnosed with major depressive disorder (MDD), and had been prescribed with 12.5mg/day three times per day [17]. This individual suffered withdrawal after 6 months from the same dosage, and increased dose to evade withdrawal [17]. Withdrawal symptoms included palpitations, sweating, nausea, and trembling [17; 18]. The individual then became reliant on tianeptine with consumption 150-175mg six times per day [17]. Tianeptine abuse cases have also reported that some cases’ main motivation was ‘to get high’ from tianeptine [1]. Other adverse reports have indicated 15 cases of overdose with tianeptine, with 3 resulting in death [1].

References

[1] Rahul Lauhan, Alan Hsu, Al Alam, Kristin Beizai, 2018. Tianeptine Abuse and Dependence: Case Report and Literature Review. Psychosomatics 2018:17.

[2] Nahida Tabassum, Saima Rasool, Zafar Ahmad Malik, Feroz Ahmad, 2012. Natural Cognitive Enhancers. Journal of Pharmacy Research 2012,5(1),153-160.

[3] Rajapaksha Gedara Prasad Tharanga Jayasooriya, Matharage Gayani Dilshara, Yung Hyun Choi, Sung-Kwon Moon, Wun-Jae Kim, Gi-Young Kim, 2014. Tianeptine sodium salt suppresses TNF-alpha -induced expression of matrix metalloproteinase-9 in human carcinoma cells via suppression of the PI3K/Akt-mediated NF-kB pathway. environmental toxicology and pharmacology 38 (2014) 502–509.

[4] Muhammad Irfan, Sumeira Rabel, Quratulain Bukhtar, Muhammad Imran Qadir, Farhat Jabeen, Ahmed Khan, 2016. Orally disintegrating films: A modern expansion in drug delivery system. Saudi Pharmaceutical Journal, 24, 537-546.

[5] Dhere P.M. . Patwekar S.L, 2011. Review on preparation and evaluation of oral disintegrating films. International Journal Of Pharmacy & Technology, 3(4), 1572-1585.

[6] Christiaan B. Brink, Brian H. Harvey and Linda Brand, 2006. Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of Depression. Recent Patents on CNS Drug Discovery,2006, 1, 29-41.

[7] Hüseyin Çetin Ketenci, Emel Çakır, Nazım Ercüment Beyhun, Halil Boz, Hasan Okumuş, Gökhan Cingöz, Bülent Şam, 2018. Death Due to Tianeptine Injection Through Inguinal Incision: Two Case Reports. Adli Tıp Bülteni, 2018; 23(2): 123-128.

[8] Jangsup Moon, Keun-Hwa Jung, Jung-won Shin, Jung-Ah Lim, Jung-Ick Byun, Soon-Tae Lee, Kon Chu, Sang Kun Lee, 2014. Safety of tianeptine use in patients with epilepsy. Epilepsy & Behavior 34 (2014) 116–119. http://dx.doi.org/10.1016/j.yebeh.2014.03.021.

[9] MM Gassaway, M-L Rives, AC Kruegel, JA Javitch and D Sames, 2014. The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonist. Transl Psychiatry (2014) 4, e411; doi:10.1038/tp.2014.30.

[10] Małgorzata Szafarz, Agnieszka Wencel & Krzysztof Pociecha & Filip A. Fedak & Piotr Wlaź & Elżbieta Wyska, 2018. Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method. Naunyn-Schmiedeberg’s Archives of Pharmacology (2018) 391:185–196 https://doi.org/10.1007/s00210-017-1448-2.

[11] Fond G, Micoulaud-Franchi JA, Macgregor A, Richieri R, Miot S, Lopez R, Abbar M, Lancon C and Repantis D, 2015. Neuroenhancement in Healthy Adults, Part I: Pharmaceutical Cognitive Enhancement: A Systematic Review. J Clinic Res Bioeth 2015, 6:2.

[12] Tanja Frančišković, Zoran Šuković, Sanja Janović, Aleksandra Stevanović, Iva Nemčić-Moro, Ika Rončević-Gržeta & Marina Letica-Crepulja, 2011. Tianeptine in the combined treatment
of combat related posttraumatic stress disorder. Psychiatria Danubina, 2011; Vol. 23, No. 3, pp 257–263.

[13] Vladimir Novotny and Frantisek Faltus, 2002. Tianeptine and fluoxetine in major depression: a 6-week randomised double-blind study. Hum Psychopharmacol Clin Exp 2002; 17: 299–303. DOI: 10.1002/hup.411.

[14] Lionel Waintraub, Lucia Septien and Paul Azoulay, 2002. Efficacy and Safety of Tianeptine in

Major Depression. Evidence from a 3-Month Controlled Clinical Trial versus Paroxetine. CNS Drugs 2002; 16 (1): 65-75 1172-7047/02/0001-0065/$22.00/0.

[15] Fran Ridout and Ian Hindmarch, 2001. Effects of tianeptine and mianserin on car driving skills. Psychopharmacology (2001) 154:356–361. DOI 10.1007/s002130000662.

[16] Adam Klasik, Krzysztof Krysta & Irena Krupka-Matuszczyk, 2011. Effect of tianeptine on cognitive functions in patients with depressive disorders during a 3-month observation. Psychiatria Danubina, 2011; Vol. 23, Suppl. 1, pp 18–22.

[17] Syed Nabil, Ng Chong Guan, Rusdi Abd Rashid, 2018. Tianeptine Dependence: A Case Report. MJP Online Early.

[18] P. Brambilla, A. Cipriani, M. Hotopf and C.Barbui, 2004. Side-Effect Profile of Fluoxetine in Comparison with Other SSRIs, Tricyclic and Newer Antidepressants: A Meta-Analysis of Clinical Trial Data. Pharmacopsychiatry 2005; 38: 69±77.